<DOC>
	<DOCNO>NCT01462812</DOCNO>
	<brief_summary>The study conduct determine OPTINOSE SUMATRIPTAN deliver nasally ( nose ) use OPTINOSE SUMATRIPTAN Device reduce pain symptom associate migraine headache .</brief_summary>
	<brief_title>Safety &amp; Efficacy Single Dose Sumatriptan Powder Delivered Intranasally With Bi-directional Device Adults With Acute Migraine</brief_title>
	<detailed_description>The primary objective study compare headache relief ( define reduction moderate [ Grade 2 ] severe [ Grade 3 ] pain none [ Grade 0 ] mild [ Grade 1 ] pain ) 120 minute follow dose 20 mg OPTINOSE SUMATRIPTAN placebo acute treatment single migraine attack .</detailed_description>
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Sumatriptan</mesh_term>
	<criteria>Men woman , age 18 65 year Diagnosis migraine , without aura Experiences 1 8 migraine attack per month past 12 month Inability distinguish headache migraine Experiences headache kind frequency great equal 15 day per month History resistance sumatriptan , nonresponse 2 triptans , define subject respond adequate dose duration treatment Current use medication migraine prophylaxis stable ( dose adjustment ) 30 day prior screen Chronic opioid therapy ( &gt; 3 consecutive day 30 day prior screen )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Migraine</keyword>
	<keyword>Headache</keyword>
	<keyword>Sumatriptan</keyword>
</DOC>